El coste de vacunar a lo largo de toda la vida en España

Soneira, Marta Soler; Lucerón, Carmen Olmedo; Cejudo, Laura Sánchez-Cambronero; Gudino, Elena Cantero; Sánchez, Aurora Limia

doi:10.4321/s1135-57272020000100016

Cited by 11 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The only difference in the vaccination schedule between men and women in this study was the HPV vaccine, which costs an estimated total of around 100 euros per healthy person for the 3 doses (29.16 euros per dose). 74 Comparable results have been reported for other Western European countries. 75 …”

Section: Discussionmentioning

confidence: 52%

Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019

Carazo-Casas

Gil-Prieto

Hernández‐Barrera

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, and prevalence is still substantially higher in men than in women. Causative factors include smoking and alcohol use, while human papillomavirus (HPV) infection is causally related to a subset of oropharyngeal cancers. In this retrospective study, we aimed to provide estimates on the clinical and economic burden of HNSCC in Spain. Methods We used the discharge reports from the Spanish Minimum Basic Data Set (MBDS), to retrospectively analyze hospital discharge data in individuals with a diagnosis of HNSCC in any diagnostic position, based on the ICD coding system (ICD-9-CM and ICD10 CM), from 2009 to 2019. Results A total of 175,340 admissions and 14,498 deaths due to laryngeal, pharyngeal and oral cavity cancer were recorded in Spain, of which 85% occurred in men. The most prevalent diagnoses were laryngeal cancer in men (50.9%) and oral cavity cancer in women (49.1%). In general, the hospitalization and death rates for all major head and neck cancer sites decreased in men and increased or remained stable in women during the study period. However, the corresponding rates for tonsil cancer, strongly associated with HPV infection, increased significantly in men. Overall, the economic burden of HNSCC during the study period was estimated at 100 million euros per year on average. Conclusion HNSCC still places an important clinical and economic burden on the health system in Spain. Prevention strategies should be prioritized, and vaccination programs against HPV in both sexes should be reinforced.

show abstract

Section: Discussionmentioning

confidence: 52%

Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019

Carazo-Casas

Gil-Prieto

Hernández‐Barrera

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…También es importante destacar que, a pesar del aumento del coste del calendario vacunal en los últimos años, debido al gasto sanitario que supone el tratamiento de las enfermedades que pueden ser prevenidas por la vacunación, es rentable vacunar a las personas a lo largo de su vida principalmente a aquellas con factores de riesgo. Asimismo, no se debe olvidar que con el progresivo envejecimiento de la población, Una importante parte del coste sanitario producido por las enfermedades inmunoprevenibles podría disminuir si se aumentase la cobertura de vacunación en la edad adulta (26).…”

Section: Discussionunclassified

Hospital disease burden due to influenza and its comorbidities in Spain (2016-2021)

Díaz Gil,

Gil-Prieto,

Hernández Barrera

et al. 2024

an. ranm

View full text Add to dashboard Cite

Background: Influenza is an infectious disease that can lead to complications requiring hospitalization and may even result in death, particularly in patients at extreme ages. Our objective is to analyze hospitalized patients with an ICD-10 diagnostic code for influenza (codes J09, J10, and J11) in any diagnostic position from 2016 to 2021 in the Spanish hospital surveillance system. Methods: Information on age, admissions, length of hospital stay, lethality, mortality, and comorbidity with a diagnostic code for influenza between October 1, 2016, and September 30, 2021, was obtained from the National Hospital Data Surveillance System (Conjunto Mínimo Básico de Datos, CMBD). Results: A total of 118,585 hospital admissions with an influenza diagnose were recorded. Out of these, 57,671 patients (48.63%) were males, while 60,914 (51.37%) were females. The overall median age of admissions was 70.5 years. Significant differences were found among different age groups, with those over 65 years being the largest group in this study. The hospitalization rate for the entire period was 42.13 cases per 100,000 inhabitants. The overall mortality rate for the observed period was 2.45 deaths per 100,000 inhabitants, being higher in the group over 85 years. The most common comorbidity in the studied patients was diabetes mellitus, followed by chronic obstructive pulmonary disease and congestive heart failure. The latter group showed higher lethality than those patients with any other comorbidity. The average length of hospital stay was 9.59 days. Conclusions: Influenza is an important cause of hospitalization in Spain. Male gender, older age groups, and associated clinical risk conditions showed a direct relationship with hospital mortality. This suggests that influenza vaccination should be implemented in the population to reduce associated comorbidities, as well as the mortality resulting from them.

show abstract

“…Administration costs were taken from the analysis performed by the Spanish Ministry of Health, which estimated an average cost of €6 to administer a vaccination dose (20). As the two Rotarix® doses (months 2 and 4) coincide with other vaccines included in the Spanish routine vaccination schedule, we reduced the cost by half.…”

Section: Costsmentioning

confidence: 99%

Updating and refining of economic evaluation of rotavirus vaccination in Spain: A cost-utility analysis

Imaz-Iglesia

Carmona

García-Carpintero

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Two vaccines against rotavirus diseases, Rotarix® and RotaTeq®, are being marketed in Spain; but rotavirus is not among diseases covered by universal vaccination in Spain. The aim was to assess the efficiency of extending Spain’s current targeted rotavirus vaccination strategy including only preterm babies, to a policy of universal vaccination. Methods A de novo cohort-based Markov model was built to evaluate the efficiency of three rotavirus vaccination strategies in Spain, i.e., targeted, universal, and no vaccination. Using Rotarix® or RotaTeq®, we compared the cost-utility of these strategies from both a societal and Spanish National Health System (SNHS) perspective. The model represents the most important clinical events conceivably linked to rotavirus infection. Efficacy, effectiveness, safety, costs and utilities were identified by systematic reviews. Results Incremental cost-utility threshold (ICUR) is €23,638/QALY (Quality Adjusted Life Year) for targeted vaccination with Rotarix®. The ICUR for the rest of the strategies evaluated are above €30,000/QALY. Sensitivity analysis shows the price as the only parameter that could make the universal vaccination strategy efficient. Conclusions Considering a threshold of €25,000/QALY, only targeted vaccination with Rotarix® from the societal perspective would be efficient. Price drops of 36.9% for Rotarix® and 44.6% for RotaTeq® would make universal vaccination efficient.

show abstract

El coste de vacunar a lo largo de toda la vida en España

Cited by 11 publications

References 16 publications

Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019

Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019

Hospital disease burden due to influenza and its comorbidities in Spain (2016-2021)

Updating and refining of economic evaluation of rotavirus vaccination in Spain: A cost-utility analysis

Contact Info

Product

Resources

About